Novartis AG (NVS)
97.46
+0.19
(+0.20%)
USD |
NYSE |
May 06, 13:16
Novartis Price to Book Value: 5.012 for May 6, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 5.002 |
| May 02, 2024 | 5.006 |
| May 01, 2024 | 5.014 |
| April 30, 2024 | 4.995 |
| April 29, 2024 | 4.993 |
| April 26, 2024 | 5.011 |
| April 25, 2024 | 5.094 |
| April 24, 2024 | 5.058 |
| April 23, 2024 | 5.003 |
| April 22, 2024 | 4.892 |
| April 19, 2024 | 4.853 |
| April 18, 2024 | 4.761 |
| April 17, 2024 | 4.787 |
| April 16, 2024 | 4.793 |
| April 15, 2024 | 4.855 |
| April 12, 2024 | 4.810 |
| April 11, 2024 | 4.852 |
| April 10, 2024 | 4.854 |
| April 09, 2024 | 4.927 |
| April 08, 2024 | 4.910 |
| April 05, 2024 | 4.926 |
| April 04, 2024 | 4.983 |
| April 03, 2024 | 4.853 |
| April 02, 2024 | 4.855 |
| April 01, 2024 | 4.930 |
| Date | Value |
|---|---|
| March 31, 2024 | |
| March 28, 2024 | 4.237 |
| March 27, 2024 | 4.200 |
| March 26, 2024 | 4.173 |
| March 25, 2024 | 4.193 |
| March 22, 2024 | 4.215 |
| March 21, 2024 | 4.208 |
| March 20, 2024 | 4.207 |
| March 19, 2024 | 4.219 |
| March 18, 2024 | 4.201 |
| March 15, 2024 | 4.260 |
| March 14, 2024 | 4.298 |
| March 13, 2024 | 4.336 |
| March 12, 2024 | 4.37 |
| March 11, 2024 | 4.44 |
| March 08, 2024 | 4.411 |
| March 07, 2024 | 4.377 |
| March 06, 2024 | 4.496 |
| March 05, 2024 | 4.472 |
| March 04, 2024 | 4.466 |
| March 01, 2024 | 4.470 |
| February 29, 2024 | 4.422 |
| February 28, 2024 | 4.477 |
| February 27, 2024 | 4.518 |
| February 26, 2024 | 4.522 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
2.588
Minimum
Sep 26 2022
5.469
Maximum
Oct 02 2023
3.726
Average
3.784
Median
Price to Book Value Benchmarks
| Roche Holding AG | 5.491 |
| Sandoz Group AG | -- |
| Amgen Inc | 31.97 |
| Incyte Corp | 2.251 |
| MorphoSys AG | 49.82 |
Price to Book Value Related Metrics
| PE Ratio | 13.30 |
| PS Ratio | 4.051 |
| PEG Ratio | 0.1059 |
| Price to Free Cash Flow | 19.74 |
| Price | 97.46 |
| Earnings Yield | 7.52% |
| Market Cap | 198.86B |
| PEGY Ratio | 0.1027 |
| Operating PE Ratio | 19.01 |
| Normalized PE Ratio | 22.05 |